Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States

Conference Correspondent - TON - ASH 2015 - Multiple Myeloma

The incidence of multiple myeloma is nearly 2-fold higher in African Americans than in whites. There are also differences in overall survival between the 2 races. This difference is not completely explained by racial disparities, and researchers postulate that some of the differences may be attributable to genetic variations between the 2 groups.

Using data from the National Cancer Institute, researchers examined differences in the incidence, mortality, and survival of 68,701 white, 16,364 black, and 4802 other patients with MM who were classified by race, sex, and age, from 1973 to 2012. Age-adjusted incidence and mortality rates, regression analysis, and survival curves were calculated by race. Median age at diagnosis was 66 years for African Americans and 71 years for whites (P <.01).

The age-adjusted incidence rates per 100,000 population for African Americans (11.9; P <.05) were more than double the corresponding rates for whites (5.1). African Americans present with myeloma at a lower age compared with whites, and this difference was seen during the course of the study.

Although 5-year relative survival is improving for all races and sexes, the survival analysis showed that African American race is an independent factor for improved survival (hazard ratio, 0.884; P <.0001). Further population-based studies focused on how exploring the underlying biologic mechanisms of disease may explain unanswered questions such as higher incidence rates and better overall survival among African American patients.

Related Items
Evaluation of Geriatric Assessment Tools in Elderly Patients with MM
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
The Significant Contribution of Pain in Determining the Health Status of Patients with Multiple Myeloma
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Incidence of Falls Is Common in Older Adults with Newly Diagnosed MM
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Improving the Management of Patients on Oral Regimens
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on December 8, 2015 in TON - ASH 2015 - Multiple Myeloma
Utilizing Patient Support Services
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Natural History of Relapsed MM After Initial Relapse
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Ixazomib plus Lenalidomide/Dexamethasone Significantly Prolongs Progression-Free Survival for Patients with RRMM in the Phase 3 Tourmaline-MM1 Study
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
The Relevance of Minimal Residual Disease Monitoring in Elderly Multiple Myeloma Patients
Conference Correspondent published on December 7, 2015 in TON - ASH 2015 - Multiple Myeloma
Last modified: December 8, 2015